Related Experiment Video

Updated: Aug 13, 2026

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

[Aggressive diffuse lymphoma with malignant pleural effusion expressing c-erbB-2 (neu) oncogene products]

M Mineshita1, T Miyazawa, M Doi

  • 1Department of Respiratory Medicine, Hiroshima City Hospital, Japan.

Nihon Kyobu Shikkan Gakkai Zasshi
|June 1, 1993
PubMed

Insights

This study reports a rare case of diffuse large B-cell lymphoma in an elderly male. The malignant cells expressed c-neu, suggesting its potential as a prognostic indicator for lymphoproliferative disorders.

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Malignant lymphoma (ML) is a significant hematologic malignancy.
  • Accurate diagnosis and prognostic indicators are crucial for patient outcomes.
  • Diffuse large B-cell lymphoma (DLBCL) is an aggressive subtype requiring effective therapeutic strategies.

Observation:

  • An 83-year-old male presented with pleural effusion and lymphadenopathy.
  • Pathological diagnosis confirmed diffuse, large cell, non-cleaved type ML.
  • Malignant cells exhibited coexpression of CD10, CD19, CD20, CD22, CD24, CD38, Ia, c-neu, and surface immunoglobulin G kappa.

Findings:

  • Flow cytometry analysis revealed specific surface phenotypes of ML cells.
  • High expression of NRAS p21 was detected via cytoplasmic immunofluorescence.
  • The patient's rapid decline and death underscore the aggressive nature of the disease.

Implications:

  • The c-neu oncoprotein, typically associated with breast cancer, was found on ML cells.
  • c-neu expression may serve as a novel prognostic marker in lymphoproliferative disorders.
  • Further research is warranted to validate c-neu as a prognostic indicator in lymphoma.

More Related Videos

Enhancing Tumor Content through Tumor Macrodissection10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines08:01

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Published on: April 21, 2022

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Pleural Effusion I: Introduction01:25

Pleural Effusion I: Introduction

Pleural effusion is an abnormal fluid accumulation in the pleural cavity, a narrow space between the lungs and the chest wall. It is not a disease per se but rather a symptom or indication of an underlying disease. In normal circumstances, this space contains a small amount of fluid (5 to 15 mL), a lubricant facilitating the non-frictional movement of the pleural surfaces.
There are two main types of pleural effusion: transudative and exudative. They are differentiated using Light's criteria,...
Pleural Effusion II: Symptoms and Management01:28

Pleural Effusion II: Symptoms and Management

Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations: